Latest From ShangPharma Corp.
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
China’s healthcare sector was back to actively raising proceeds from the capital markets in March and April, which witnessed more than 20 IPOs in total, with a stream of other listings being planned.
Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- ShangPharma Corp.
- Senior Management
Michael Xin Hui, Chmn. & CEO
William Dai, CFO
Jennifer He , VP, Fin.
Yajun Xu, PhD, SVP, Corp. Dev.
Art Taveras, PhD, Pres. & CSO
- Contact Info
Phone: (86) 21 5132 0088
998 Halei Rd., Zhangjiang Hi-Tech Park
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.